What is kisqali for?

What does Kisqali treat?

Kisqali is a CDK4/6 inhibitor used with hormone therapy to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It works by blocking enzymes that allow cancer cells to divide and grow.

How long does treatment last?

Treatment continues until disease progression or unacceptable side effects occur. Patients may receive it alone or combined with an aromatase inhibitor or fulvestrant.

What happens if treatment stops early?

Early discontinuation often relates to side effects like low white blood cell counts, liver enzyme changes, or QT interval prolongation. Patients who stop early may need alternative therapies.

Why is Kisqali different from other CDK4/6 inhibitors?

Kisqali contains ribociclib and differs from palbociclib (Ibrance) and abemaciclib (Verzenio) in its dosing schedule and cardiac monitoring requirements. Some studies show broader survival benefits in certain patient groups.

When does the patent expire?

Kisqali’s compound patent expires in 2031, but secondary patents and regulatory exclusivities may extend market protection. [1]

Kisqali is marketed by Novartis.